Busch T, Skiljic D, Rudolph T, et al. - Researchers conducted this retrospective study to describe the 1-year-outcome of XEN 45 gel stent surgery in a Swedish cohort with regard to clinical success, complications, and learning curve. The sample consisted of glaucoma patients undergoing glaucoma XEN-stent surgery alone or combined with phacoemulsification between December 2015 and May 2017. Intraocular pressure (IOP), number of medical agents, and adverse events have been assessed. In total, 113 eyes were involved in the final statistics. Data reported that primary open angle glaucoma (POAG) accounted for 46.9% and exfoliative glaucoma (PEXG) for 40.7%. In both POAG and PEXG, XEN-stent surgery is a surgical option for uncontrolled glaucoma. A XEN-stent can decrease both the IOP and the number of medications required for antiglaucoma. The learning curve is significant and stent positioning is crucial for optimal outcomes. Findings suggested that combined XEN-cataract surgery is not inferior to stand-alone procedures. Long-term efficacy needs to be established.